Brokerages predict that Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) will announce earnings per share of ($0.25) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Sunesis Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate coming in at ($0.33). Sunesis Pharmaceuticals posted earnings per share of ($0.44) during the same quarter last year, which suggests a positive year over year growth rate of 43.2%. The business is scheduled to report its next earnings results on Thursday, March 8th.
According to Zacks, analysts expect that Sunesis Pharmaceuticals will report full-year earnings of ($1.58) per share for the current fiscal year, with EPS estimates ranging from ($1.66) to ($1.48). For the next year, analysts forecast that the business will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.16) to ($0.80). Zacks’ EPS averages are a mean average based on a survey of research analysts that follow Sunesis Pharmaceuticals.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.06). During the same quarter in the previous year, the company earned ($0.62) EPS.
Shares of Sunesis Pharmaceuticals (NASDAQ SNSS) opened at $4.01 on Friday. Sunesis Pharmaceuticals has a 52 week low of $1.82 and a 52 week high of $4.45. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of -0.34. The firm has a market cap of $136.96, a price-to-earnings ratio of -2.29 and a beta of 1.53.
In other Sunesis Pharmaceuticals news, major shareholder Mpm Oncology Impact Management purchased 25,300 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The shares were bought at an average cost of $2.59 per share, for a total transaction of $65,527.00. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director Dayton Misfeldt purchased 400,000 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The shares were acquired at an average price of $2.00 per share, for a total transaction of $800,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 506,800 shares of company stock worth $1,091,282 over the last 90 days. 10.21% of the stock is currently owned by corporate insiders.
Several hedge funds have recently made changes to their positions in SNSS. Balyasny Asset Management LLC purchased a new stake in shares of Sunesis Pharmaceuticals during the 2nd quarter valued at approximately $5,400,000. Virtu KCG Holdings LLC bought a new stake in Sunesis Pharmaceuticals during the 2nd quarter worth approximately $208,000. Wells Fargo & Company MN increased its holdings in Sunesis Pharmaceuticals by 127.6% during the 3rd quarter. Wells Fargo & Company MN now owns 95,247 shares of the biopharmaceutical company’s stock worth $185,000 after acquiring an additional 53,396 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Sunesis Pharmaceuticals by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after acquiring an additional 23,819 shares during the period. Institutional investors own 38.21% of the company’s stock.
WARNING: This piece of content was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2018/01/12/sunesis-pharmaceuticals-inc-snss-expected-to-announce-earnings-of-0-25-per-share-2.html.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.